Relay Therapeutics, Inc. (RLAY) Presents at Barclays 28th Annual Global Healthcare Conference Transcript

Company Overview - Relay Therapeutics has been established for nearly 10 years, focusing on precision medicine targets [2] - The company has navigated a challenging environment for biotechs over the past few years [2] Strategic Focus - Relay Therapeutics has out-licensed its lead program, an FGFR2 inhibitor, to adapt to market conditions [2] - The company has streamlined its research organization and staggered some preclinical programs [3] Key Research Initiatives - The primary focus is now on the PI3K-alpha inhibitor, zovegalisib, which is believed to be the first mutant selective inhibitor entering clinical trials [3] - There are three major opportunities identified for zovegalisib: hormone receptor positive, HER2-negative frontline and second-line metastatic breast cancer, and PI3K-alpha-driven vascular amalgamations [3]